Chen Chen
Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, CA 92130, USA.
Curr Med Chem. 2008;15(21):2173-91. doi: 10.2174/092986708785747625.
Cetirizine, marketed as a racemic mixture containing both levocetirizine and dextrocetirizine, is a member of the second generation H(1) antihistamines clinically used for the treatment of symptoms associated with seasonal allergic rhinitis. Recently, its single R-enantiomer levocetirizine has been approved by the FDA as the newest antihistamine. Cetirizine is a piperazine derivative related to the first generation H(1) antagonist hydroxyzine, and is the major metabolite in the blood circulation after hydroxyzine administration in humans. The acid functionality of cetirizine in combination with one of the basic nitrogens of piperazine ring makes this compound a very unique zwitterion. The molecular structure of cetirizine allows its carboxylic group to interact with the basic nitrogen via folded conformers, therefore, it possesses relatively high lipophilicity at physiological pH (LogD=1.5). While both cetirizine and hydroxyzine possess high affinity at the H(1) receptor, the R-configured levocetirizine has much slower dissociation rate from the H(1) receptor than R-hydroxyzine, making it an insurmountable antagonist. In addition, the pharmacokinetics of cetirizine significantly differs from those of the basic and lipophilic hydroxyzine. For example, cetirizine has much lower CNS penetration than hydroxyzine, which may be explained by the zwitterionic structure of cetirizine and its P-glycoprotein activity. Cetirizine exhibits high intestinal absorption in humans and its oral bioavailability is estimated to be greater than 70%. Very importantly, cetirizine, especially levocetirizine, has a negligible interaction with the liver enzymes, and is mainly excreted in the urine as the parent despite its high plasma protein binding (88 approximately 96%). The recommended dose of levocetirizine is 5 mg once daily, while its pharmacokinetic half-life is about 7 h in humans. This review will focus on the physicochemical, pharmacological and pharmacokinetic properties of cetirizine and levocetirizine in comparison with those of hydroxyzine. The zwitterionic cetirizine displays distinct advantages over the basic hydroxyzine in several categories such as slow receptor dissociation rate, high selectivity, negligible liver enzyme interaction and low CNS penetration. Therefore, cetirizine, or its single isomer levocetirizine, might serve a good example for medicinal chemists to design zwitterionic drugs from a basic, acidic or neutral lead molecule for peripheral biological targets.
西替利嗪以含有左西替利嗪和右西替利嗪的消旋混合物形式上市,是第二代H(1)抗组胺药的一种,临床上用于治疗与季节性变应性鼻炎相关的症状。最近,其单一R-对映体左西替利嗪已被美国食品药品监督管理局(FDA)批准为最新的抗组胺药。西替利嗪是一种与第一代H(1)拮抗剂羟嗪相关的哌嗪衍生物,是人体服用羟嗪后血液循环中的主要代谢产物。西替利嗪的酸性官能团与哌嗪环的一个碱性氮原子结合,使该化合物成为一种非常独特的两性离子。西替利嗪的分子结构使其羧基能够通过折叠构象与碱性氮原子相互作用,因此,它在生理pH值下具有相对较高的亲脂性(LogD=1.5)。虽然西替利嗪和羟嗪在H(1)受体上都具有高亲和力,但R构型的左西替利嗪从H(1)受体解离的速率比R-羟嗪慢得多,使其成为一种不可逾越的拮抗剂。此外,西替利嗪的药代动力学与碱性和亲脂性羟嗪的药代动力学有显著差异。例如,西替利嗪的中枢神经系统穿透力比羟嗪低得多,这可能由西替利嗪的两性离子结构及其P-糖蛋白活性来解释。西替利嗪在人体中表现出高肠道吸收,其口服生物利用度估计大于70%。非常重要的是,西替利嗪尤其是左西替利嗪与肝酶的相互作用可忽略不计,尽管其血浆蛋白结合率高(约88%至96%),但主要以原形经尿液排泄。左西替利嗪的推荐剂量为每日一次5mg,但在人体中的药代动力学半衰期约为7小时。本综述将重点比较西替利嗪和左西替利嗪与羟嗪在物理化学、药理和药代动力学性质方面的异同。两性离子的西替利嗪在几个方面显示出比碱性羟嗪明显的优势,如受体解离速率慢、选择性高、肝酶相互作用可忽略不计和中枢神经系统穿透力低。因此,西替利嗪或其单一异构体左西替利嗪可能为药物化学家从碱性、酸性或中性先导分子设计用于外周生物学靶点的两性离子药物提供一个很好的例子。